Target intelligence / Profile preview

Mastermind-like protein 1 (MAML1)

Target
MAML1
Molecular classification
Transcriptional coactivator, Transcription factor (coactivator role), Regulatory protein, Nuclear protein, Other (pleiotropic coactivator for multiple signaling pathways)
01

Overview

Mastermind-like protein 1 (MAML1) is a nuclear transcriptional coactivator that acts as a central integrator of the Notch signaling cascade by forming a ternary complex with the Notch intracellular domain and CSL DNA-binding protein, thereby activating target gene expression. MAML1 also modulates other major pathways, particularly Wnt/β-catenin-mediated transcription, and interacts with pivotal transcription factors such as MEF2C and p53, coordinating cellular processes including differentiation, proliferation, and apoptosis. Alterations in MAML1 activity are implicated in the development of diverse malignancies and muscle diseases, positioning it as a key node in transcriptional regulation and a potential point of therapeutic intervention.

Other names
Mastermind-like transcriptional coactivator 1KIAA0200Mam-1mastermind homologMam1mastermind-like 1MAML1
02

Mechanism of action

Indirect inhibition via Notch pathway antagonists (such as γ-secretase inhibitors, which prevent the formation of the active Notch intracellular domain needed for MAML1 complex formation). Dominant-negative MAML1 constructs used experimentally block coactivation functions.

03

Biological functions

Regulation of Notch signaling (cell fate determination)Coactivation of Wnt/β-catenin transcriptionMuscle differentiation (coactivator for MEF2C)p53 stabilization and transcriptional coactivationCell proliferationCell deathSignal transductionCross-talk between major developmental pathways
04

Disease associations

Cancer (particularly colorectal, breast, leukemia, and other tumors with aberrant Wnt/β-catenin or Notch signaling)Muscular dystrophyOther developmental disorders possibly resulting from disrupted Notch signaling
05

Safety considerations

Targeting coactivators like MAML1 may cause off-target effects due to their role in multiple essential signaling pathways.Inhibition may impair normal tissue regeneration, immune function, and muscle development.Possible toxicity due to broad pathway involvement.
06

Interacting drugs

Notch signaling inhibitors (e.g., γ-secretase inhibitors)

2 more in the full profile.

07

Biomarkers

No established MAML1-specific clinical biomarkers.Expression of MAML1 and Notch target genes (e.g., HES1, cyclin D1, c-Myc) may serve as surrogate markers of pathway activation in disease contexts.

Beyond the preview

Go deeper on Mastermind-like protein 1 (MAML1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mastermind-like protein 1 (MAML1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call